Precision medicine regulatory strategy
Biomarker and patient-selection evidence translated into a defensible regulatory position, built around how a health authority will actually review it.
Strategy and execution for the therapeutics, companion diagnostics and biomarker-driven programmes at the centre of precision medicine — coordinated across FDA, EMA, MHRA and EU IVDR requirements.
WHAT WE COVER
Biomarker and patient-selection evidence translated into a defensible regulatory position, built around how a health authority will actually review it.
Coordinated therapeutic and diagnostic development plans so the CDx and the drug or biologic move through analytical validation, clinical evidence and review in step.
Submission-ready packages spanning IDE, 510(k), De Novo and PMA in the US, and EU IVDR technical documentation and Annex XIV filings for Class C companion diagnostics.
Filing strategy, health-authority interaction and lifecycle management across FDA, EMA, MHRA and other regional bodies, kept in step with the paired therapeutic submission.
WAYS TO ENGAGE
Determine the fastest defensible regulatory route for a diagnostic tied to a therapeutic label claim.
Ongoing regulatory ownership across the paired therapeutic and diagnostic workstreams.
Build and quality-check IDE, PMA, 510(k), De Novo or IVDR technical files before they are filed.
GO DEEPER
Submission strategy, health-authority meetings and fractional regulatory leadership.
See the overview →The application planning, SOP governance and CTD authoring work behind every submission.
Explore Operations →START WITH THE CONSTRAINT
Tell us the decision, deliverable or role you are working through. We will help identify the most useful next step.